PALONOSETRON HCL CAS NO.135729-62-3

Product Name:    Palonosetron Hydrochloride
Synonyms:    (S)-2-((S)-quinuclidin-3-yl)-2,3,3a,4,5;Palonosetron hydrochloride, 99.5%, a 5-HT3 antagonist;PALONOSETRON HCL;PALONOSETRON HYDROCHLORIDE;CS-292;Palonosetronhydrochloride hydrochloride;Palonosetron-d3 HCl;(3aS)-2-(3S)-1-Azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one Hydrochloride
CAS:    135729-62-3
MF:    C19H25ClN2O
MW:    332.87
EINECS:    680-630-6
Product Categories:    Selective 5-HT3 Receptor Antagonist;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API
Mol File:    135729-62-3.mol

Melting point     >290°C
alpha     D25 -94.1° (c = 0.4 in water)
storage temp.     Inert atmosphere,Store in freezer, under -20°C
Merck     14,6997
CAS DataBase Reference    135729-62-3(CAS DataBase Reference)
Safety Information
HS Code     29339900

Nausea and vomiting drug    Palonosetron hydrochloride is a drug to inhibit nausea and vomiting, which is a new type highly selective, high-affinity 5-HT3 receptor antagonist that can block the vomiting reflex center peripheral neurons presynaptic 5-HT. Receptor excitement directly affects the central nervous system in 5-HT. Impulse receptor excitement generated by the role of vagal afferent nerve after area, blocking the vagus nerve endings in the gut, preventing signals to 5-HT. Receptor trigger zone can reduce the incidence of nausea and vomiting. Central clinically for the treatment of acute severe emetogenic chemotherapy induced delayed nausea and vomiting. Because of its high curative effect, little side effect, long half-life (about 40 h), small dosage, and so on, it has attracted much attention.
With 1,2,3,4-tetrahydro-1-naphthoic acid as the starting material, the split, amination, reduction, cyclization, salt of palonosetron hydrochloride granisetron.
Clinical studies showed that palonosetron can be used safely with corticosteroids, analgesics, antiemetics, antispasmodics and anticholinergic drugsas the starting material, the split, amination, reduction, cyclization, salt of palonosetron hydrochloride granisetron.
Murine tumor model studies indicate that palonosetron does not inhibit the five kinds of chemotherapy drugs studied (cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) anti-cancer activity.